| Dr Scott Joseph Morledge-hampton, MD | |
|
1747 Poly Dr, Billings, MT 59102-1728 | |
| (406) 294-1994 | |
| (406) 294-1996 |
| Full Name | Dr Scott Joseph Morledge-hampton |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Location | 1747 Poly Dr, Billings, Montana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1487689204 | NPI | - | NPPES |
| 0157274 | Medicaid | MT | |
| 000094566 | Other | MT | BLUE CROSS BLUE SHIELD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 10586 (Montana) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Scott Joseph Morledge-hampton, MD 1747 Poly Dr, Billings, MT 59102-1728 Ph: (406) 294-1994 | Dr Scott Joseph Morledge-hampton, MD 1747 Poly Dr, Billings, MT 59102-1728 Ph: (406) 294-1994 |
News Archive
University of Toronto researchers have found that the portfolio diet, a plant-based way of eating previously shown to lower cholesterol levels, reduces other risk factors for cardiovascular disease including blood pressure, triglycerides and inflammation.
New technologies allow users to do things like race their real bikes against other real people in a virtual world, and a new study outlines what motivates people to use these online platforms. The findings offer insights for future iterations of these technologies - and how to market them.
Dysmenorrhea, that is, frequent severe and painful cramps during menstruation from abnormal contractions of the uterus, is the most common of all gynecological disorders. It affects between 16-91% of girls and women of reproductive age, of whom 2%-29% have symptoms severe enough to restrict their daily activity.
ScinoPharm and Foresee Pharmaceuticals, Inc. jointly announced today that an investment agreement to form a joint venture has been signed. This venture looks to develop a series of peptide injectable drugs with the first being a new oncological Leuprolide injectable drug product, where Leuprolide will be formulated in a proprietary controlled-release drug delivery system originally developed by Foresee and transferred to the joint venture.
Soy-protein based infant formulas have been used to treat infants who have food allergies or intolerances.
› Verified 8 days ago
Jerald A. Bell, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 801 N 29th St, Billings, MT 59101 Phone: 406-238-2501 | |
Deborah G. Keenum, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 801 N 29th St, Billings, MT 59101 Phone: 406-238-2500 | |
Daniel T. Weaver, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 801 N 29th St, Billings, MT 59101 Phone: 406-238-2500 | |
James S. Good, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 2825 8th Ave N, Billings, MT 59101 Phone: 406-238-2500 | |
James Randall, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 1221 N 26th St, Billings, MT 59101 Phone: 406-252-5681 Fax: 406-252-5025 | |
James Peter Cornetet, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 801 N 29th St, Billings, MT 59101 Phone: 406-238-2500 | |
James Thomas Priddy, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 4033 Avenue B, Billings, MT 59106 Phone: 406-256-6000 Fax: 406-256-9006 |